Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

A. M. Evens; K. R. Carson; J. Kolesar; C. Nabhan; I. Helenowski; N. Islam; B. Jovanovic; P. M. Barr; P. F. Caimi; S. A. Gregory; L. I. Gordon

doi:10.1093/annonc/mdu179

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

A. M. Evens
, K. R. Carson
, J. Kolesar
, C. Nabhan
, I. Helenowski
, N. Islam
, B. Jovanovic
, P. M. Barr
, P. F. Caimi
, S. A. Gregory
, L. I. Gordon

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1449
Number of pages	1
Journal	Annals of Oncology
Volume	25
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdu179
State	Published - Jul 2014

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdu179

Fingerprint

Dive into the research topics of 'Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414'. Together they form a unique fingerprint.

Cite this

Evens, A. M., Carson, K. R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P. M., Caimi, P. F., Gregory, S. A., & Gordon, L. I. (2014). Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414. Annals of Oncology, 25(7), 1449. https://doi.org/10.1093/annonc/mdu179

@article{2e4e4da882a44589a9cccdff9576d85c,

title = "Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414",

author = "Evens, \{A. M.\} and Carson, \{K. R.\} and J. Kolesar and C. Nabhan and I. Helenowski and N. Islam and B. Jovanovic and Barr, \{P. M.\} and Caimi, \{P. F.\} and Gregory, \{S. A.\} and Gordon, \{L. I.\}",

year = "2014",

month = jul,

doi = "10.1093/annonc/mdu179",

language = "English",

volume = "25",

pages = "1449",

number = "7",

}

Evens, AM, Carson, KR, Kolesar, J, Nabhan, C, Helenowski, I, Islam, N, Jovanovic, B, Barr, PM, Caimi, PF, Gregory, SA & Gordon, LI 2014, 'Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414', Annals of Oncology, vol. 25, no. 7, pp. 1449. https://doi.org/10.1093/annonc/mdu179

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414. / Evens, A. M.; Carson, K. R.; Kolesar, J. et al.
In: Annals of Oncology, Vol. 25, No. 7, 07.2014, p. 1449.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi

T2 - 10.1093/annonc/mdt414

AU - Evens, A. M.

AU - Carson, K. R.

AU - Kolesar, J.

AU - Nabhan, C.

AU - Helenowski, I.

AU - Islam, N.

AU - Jovanovic, B.

AU - Barr, P. M.

AU - Caimi, P. F.

AU - Gregory, S. A.

AU - Gordon, L. I.

PY - 2014/7

Y1 - 2014/7

UR - https://www.scopus.com/pages/publications/84903732070

UR - https://www.scopus.com/pages/publications/84903732070#tab=citedBy

U2 - 10.1093/annonc/mdu179

DO - 10.1093/annonc/mdu179

M3 - Comment/debate

AN - SCOPUS:84903732070

SN - 0923-7534

VL - 25

SP - 1449

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Corrigendum to A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma [AnnOncol 2013, 24, 3076-3081] doi: 10.1093/annonc/mdt414

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this